Additionally, many patients in this study (40.4%) were previously experienced with GLP-1 RAs before their initial prescription of OW sema T2D, which may impact prescribing behavior of OW sema T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.